ストックスクリーナーアプリを入手
1.99
4.74%
0.09
アフターアワーズ：
1.99
Eagle Pharmaceuticals Inc (EGRX) 最新ニュース
EGRX STOCKHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com - Defense World
INVESTOR ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc. (EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc. (EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com - The AM Reporter
Eagle Pharmaceuticals Shares Turn Positive After Positive 2022 Outlook - marketscreener.com
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender AgreementHagens Berman - ACCESS Newswire
Latham Watkins Advises Eagle Pharmaceuticals in Royalty Monetization With Blue Owl Capital - Latham & Watkins LLP
Eagle Pharmaceuticals Announces $69 Mln Agreement To Monetize Bendeka Royalties - marketscreener.com
Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties - The Manila Times
Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale - Stock Titan
StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below 200-Day Moving Average – Here’s Why - Defense World
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan - The Manila Times
Eagle Pharmaceuticals announces amendment to limited duration stockholder rights plan - Marketscreener.com
Eagle Pharmaceuticals Doubles Anti-Takeover Protection to $20 in Rights Plan Update - Stock Titan
Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com - Defense World
Eagle Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Eagle Pharmaceuticals, Inc. (EGRX) - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
EGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX)February 9, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals, Inc. Enters Third Amended and Restated Credit Agreement - Marketscreener.com
Jane Street Group LLC Makes New Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
JPMorgan Chase & Co. Sells 63,155 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.09% - MSN
Antiemetics Drugs Market Size & Share Report, 2024 – 2032 - Global Market Insights
Last Week's Biggest Stock Movers: Eagle, Noodles & Co. - AOL
0.82%
1.62%
大文字化:
|
ボリューム (24 時間):